OSR Holdings, Inc. (OSRH)

Market Cap	13.62M -38.6%
Revenue (ttm)	2.63M -22.3%
Net Income	-9.55M
EPS	-0.39
Shares Out	35.10M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	986,999
Open	0.4100
Previous Close	0.4160
Day's Range	0.3851 - 0.4225
52-Week Range	0.3803 - 1.7900
Beta	0.61
Analysts	n/a
Price Target	n/a
Earnings Date	May 13, 2026

About OSRH

OSR Holdings, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Germany, Switzerland, and South Korea. The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma completed phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the treatment of Wilms Tumor Protein (WT1); VXM08 for Carcinoembryonic antigen (CEA); and VXM10 for PD-L1. It is also developing design-augmented (DA) bio...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Kuk Hwang
• Employees: 22
• Stock Exchange: NASDAQ
• Ticker Symbol: OSRH
• Website: https://www.osr-holdings.com

Financial Performance

In 2025, OSR Holdings's revenue was $2.91 million, a decrease of -17.69% compared to the previous year's $3.53 million. Losses were -$18.01 million, 74.4% more than in 2024.